BGM 0504
Alternative Names: BGM-0504Latest Information Update: 02 Mar 2026
At a glance
- Originator BrightGene Bio-medical technology
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity; Type 2 diabetes mellitus
Most Recent Events
- 25 Dec 2025 BrightGene Bio-Medical Technology completes a phase I trial in Obesity and Type II diabetes mellitus (In Volunteers) in China (SC, Injection) (NCT06929156)
- 23 Dec 2025 BrightGene Bio-Medical Technology initiates enrolment in phase I bioequivalence trial for Obesity in China (SC) (NCT07382908)
- 21 Oct 2025 Phase-I clinical trials in Obesity (In volunteers) in China (PO) (NCT07239973)